Mobile

Safety, Efficacy and Dose response study of BMS-986001 in subjects with HIV-1 Infection who are treatment-naive

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-003329-89

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To assess the efficacy of three doses of BMS-986001 by determining the proportion of subjects with plasma HIV-1 RNA < 50 c/mL as measured by PCR analyses at Week 24 • To assess the safety of three doses of BMS-986001 in treatment-naive HIV-1 infected subjects as measured by numbers of subjects with SAEs and numbers of subjects with AEs leading to discontinuations through Week 24, as reported on case report forms

Critère d'inclusion

  • Human Immunodeficiency Virus, Type 1 (HIV-1) Infection

Liens